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Rapid progress has been made in exploring the connections between the skeletal system and the immune system over the past 
decade. Bone tissue forms developmental niches for hematopoietic stem cells, and activated immune cells are involved in bone 
metabolism regulation and are potent mediators of osteoporosis and bone erosion under pathological conditions. The interdis-
ciplinary field of osteoimmunology has emerged to pool the knowledge of the interdependence of these two systems, including 
the shared ligands and receptors, their crosstalk and interaction, and common intracellular signaling pathways with bidirection-
al influence. The receptor activator of nuclear factor-kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) triad is 
the key vinculum, with multifaceted potency, being not only essential for osteoclastogenesis but also critical for lymph node 
organogenesis and lymphopoiesis as well as for immune regulation. In this review, we summarize the progress in this area, fo-
cusing on those aspects of interest concerning rheumatic diseases. 
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Bone is a biologically dynamic entity with permanent cell 
activity and continuous remodeling, rather than a static, 
unchanging tissue. Weight bearing, hematogenesis and co-
ordination of calcium homeostasis are the primary roles of 
bone tissue. However, immune regulation and immunogen-
esis are also key roles of bone according to updated 
knowledge about the codependence of the immune system 
and the skeletal system, as elucidated by osteoimmunology. 
Osteoblasts (OBs) originate from mesenchymal stem cells 
(MSC) and contribute to bone resorption, whereas osteo-
clasts (OCs) originate from hematopoietic precursors be-
longing to monocyte and macrophage lineages and are re-
sponsible for bone formation. Concerted bone synthesis and 
bone degradation mediate bone turnover, also known as 
bone remodeling, which helps to maintain bone density and 
bone architecture. Bone remodeling starts from the embry-
onic development period and continues throughout the 
whole lifespan, which is the fundamental adaptive mecha-
nism of bone in coping with biomechanical pressure and 
bone damage repair. If the dynamic balance of bone remod-
eling is skewed toward activated bone resorption, bone loss 
via either osteoporosis (OP) or bone erosion will occur, as 
observed in rheumatoid arthritis (RA) and other diseases 
with systemic inflammatory bone loss.  
The term “osteoimmunology” was first introduced by 
Joseph R. Arron and Yongwon Choi in 2000 (Arron and 
Choi, 2000). This new discipline has helped to demonstrate 
the concept that the skeletal system and immune system 
have an intense interaction and should be considered as a 
functional unit. Ever since 2000, cumulative evidence of the 
interplay between immune cells and bone metabolism has 
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been obtained, and clinically relevant diseases, such as RA, 
spondyloarthropathy (SPA), postmenopausal OP, and peri-
odontal disease (PD), have been investigated. This review 
will summarize current understanding in this field and con-
centrate on those aspects that interest rheumatologists.  
BONE METABOLISM 
OBs, OCs and osteocytes collaborate in continuous bone 
remodeling and bone mass renewal. OCs are specifically 
tartrate-resistant acid phosphatase (TRAP)-positive, multi-
nucleated giant cells with polarized ruffled borders that are 
involved in bone absorption. Cathepsin K, integrin 3, the 
calcitonin receptor and matrix metalloprotein 9 (MMP9) are 
the primary markers of OCs (Greisen et al., 2015), and nu-
clear factor of activated T-cells 1 (NFATc1) and c-Fos are 
the essential transcription factors for osteoclastogenesis 
(Takayanagi, 2005, 2007; Wagner and Eferl, 2005). In con-
trast, OBs are basophilic, mononuclear polygonal cells that 
contribute to bone matrix synthesis by secreting osteoid, 
embedding themselves into the matrix and then transform-
ing into osteocytes during mineralization, thus contributing 
to new bone formation. Runt-related transcription factor 2 
(Runx2) and peroxisome proliferator-activated receptor 
gamma (PPAR) are the specific transcription factors in-
volved in osteoblastogenesis (Komori, 2011). The bone 
morphogenetic protein (BMP) cascade and Wnt/-catenin 
signaling are other central players in osteoblastogenesis 
through stimulation of Runx2, thus contributing to estab-
lishing and maintaining peak bone mass (Baron et al., 2006) 
(Figure 1).  
During the physiological bone remodeling process, OCs  
 
 
Figure 1  Critical signaling molecules and transcription factors in osteoblastogenesis and osteoclastogenesis. OBs derive from mesenchymal stem cells 
(MSC) and function as bone formation cells. BMP and Wnt/-catenin are the main signaling pathways contributing to osteoblastogenesis, and Runx2 is the 
main transcription factors needed for OB differentiation and maturation and is antagonized by PPAR. Meanwhile, OCs belong to the monocyte and macro-
phage lineages and function as bone absorption cells, and the RANK-RANKL axis is the central signaling pathway in osteoclastogenesis. TREM2-DAP12 
and OSCAR-FcR associated with intracellular ITAMs are also involved. The downstream adaptor protein TRAF6 stimulates NFATc1, which is the main 
transcription factor for osteoclastogenic gene activation. Broken equilibrium of bone formation and bone absorption will lead to pathological bone remodel-
ing. FGF, fibroblast growth factor; BMP, bone morphogenetic protein; BMPR, BMP receptor; MAPK, mitogen-activated protein kinase; PI3K, phospho-
inositide 3-kinase; ERK, extracellular regulated kinase; JNK, JUN N-terminal kinase; ITAM, immunoreceptor tyrosine-based activation motif; OSCAR, 
osteoclast-associated receptor; TREM2, triggering receptor expressed on myeloid cells-2; DAP12, DNAX-activating protein 12; RANK, receptor activator of 
nuclear factor-kappa B; RANKL, RANK ligand; OPG, osteoprotegerin; TRAF6, tumor necrosis factor receptor-associated factor 6; NFATc1, nuclear factor 
of activated T-cells 1; PPAR, peroxisome proliferator-activated receptor gamma.  
 Zhao, L., et al.   Sci China Life Sci   December (2016) Vol.59 No.12 1243 
and OBs are sequentially recruited and activated. Bone re-
sorption is followed by bone formation, composing a cou-
pling of activities that is delicately regulated. Broken equi-
librium of the OBs’ and OCs’ activities leads to abnormal 
bone remodeling, with increased or decreased bone mass 
(osteopetrosis or OP, respectively). Several hormones, such 
as estrogen, parathyroid hormone (PTH), calcitonin and 
vitamin D3, are involved in bone remodeling. Estrogen ex-
hibits bone-protective effects, as revealed by the occurrence 
of OP after menopause as well as by disease alleviation 
during pregnancy and aggravation after delivery in RA pa-
tients, which parallel the waxing and waning of estrogen 
levels. In contrast, the role of PTH in regulating bone re-
modeling is much more complicated and double edged, with 
both anabolic and catabolic effects. Intermittent administra-
tion of PTH may stimulate OB differentiation and inhibit 
OB apoptosis, thus promoting bone formation. Based on 
this anabolic effect of PTH, the FDA has approved it for OP 
treatment. However, continuous injection of PTH is report-
ed to facilitate OC formation and to promote bone absorp-
tion (Qin et al., 2004). Meanwhile, calcitonin targets acti-
vated OCs and inhibits bone resorption, resulting in de-
creased serum calcium levels and increased bone mineral 
density (Karsdal et al., 2008). Finally, treatment with vita-
min D3 is beneficial for bone biology by increasing bone 
mineralization and promoting OB differentiation in vivo, in 
contrast to its pro-osteoclastogenic effects in vitro (Yoshida 
and Stern, 2012). 
STRUCTURAL AND ANATOMIC 
CONNECTIONS BETWEEN BONE CELLS AND 
IMMUNE CELLS 
Cortical bone and cancellous bone constitute the entity of 
bone tissue. The bone marrow space is loosely compart-
mentalized and accommodates hematopoietic precursors 
and trabecular bone. Bone cells and hematopoietic cells 
share this same microenvironment, with the bone marrow 
providing a milieu that allows bone cells and hematopoietic 
precursors to come into close contact and to influence each 
other. Hematopoietic precursors scatter around the trabecu-
lar bone, forming a hematopoietic focus from which im-
mune cells derive. The bone marrow is also the reservoir 
where memory T/B cells are homing to and where these 
cells survive for a long time after leaving the secondary 
lymphoid organs. The nutritive periosteal vasculature pro-
vides additional anatomic bases for further communication 
between the two systems. These vessels penetrate cortical 
bone, carrying circulatory pro-inflammatory components 
and assisting OC precursors homing from the synovium to 
bone. Endothelial cells and MSC, mature OBs and OCs, 
osteolineage-derived proteins (e.g., annexin II, angiopoietin 
I) and cytokines (e.g., interleukin (IL)-10, stem cell factor) 
participate in constructing the hematopoietic stem cell 
(HSC) niche, which is a hematopoietic microenvironment 
that supports survival and self-renewal of HSCs and con-
trols the fate of immune cells (Calvi et al., 2003; Zhang et 
al., 2003). OBs are thought to be a regulatory component of 
HSC niches that contribute to hematopoietic progenitor 
growth and HSC pool maintenance through Notch activa-
tion and osteopontin (OPN) secretion (Calvi et al., 2003; 
Nilsson et al., 2005). CXC chemokine ligand 12 (CXCL12)- 
abundant reticular cells have the potential to differentiate 
into OBs in mice and are involved in the endosteal niches 
that regulate HSC maintenance (Sugiyama and Nagasawa, 
2012). Annexin-deficient mice have decreased HSC num-
bers and impaired localization of HSCs to endosteal niches 
(Jung et al., 2007; Jung et al., 2011). In contrast, the role of 
OCs in regulating the mobilization of hematopoietic pro-
genitors and modifying HSC niches is controversial. It has 
been reported that OCs release proteolytic enzymes (e.g., 
MMP9) to degrade endosteal components and to promote 
hematopoietic progenitor mobilization into the circulation 
(Kollet et al., 2006). However, the mobilization of HSCs 
induced by serial granulocyte colony-stimulating factor 
(G-CSF) injection is normal in osteopetrotic mice lacking 
OCs, indicating that OCs are not indispensable for HSC 
maintenance and mobilization, as previously thought 
(Miyamoto et al., 2011).   
RECIPROCAL INTERACTION BETWEEN 
IMMUNE SYSTEM AND SKELETAL SYSTEM 
IMPLICATED FROM ANIMAL MODELS 
Many transcription factors and molecules are shared by the 
skeletal system and immune system. Genetically modified 
animal models shed light on the bidirectional influence of 
these mediators. In mouse models, compromised immune 
cell development and responses coexist with disturbed bone 
remodeling (Table 1).  
The Pax5 gene encodes B cell lineage-specific activator 
protein (BSAP), a transcription factor involved in B cell 
lineage commitment and development below the proB stage 
(Nutt et al., 1999). Pax5/ mice display arrested B cell de-
velopment beyond the proB stage, with severe bone loss and 
increased OC numbers (Horowitz et al., 2004). Pax5/ proB 
cells lose their B lineage commitment, while owning multi-
lineage potential. Under proper stimulation, Pax5/ proB 
cells can be induced to differentiate into OCs (Nutt et al., 
1999). PU.1 is another transcription factor and is required 
for the development of both the B lineage and the myeloid 
lineage (McKercher et al., 1999). PU.1 knockout mice ex-
hibit osteopetrosis, along with absence of OCs and macro-
phages as well as deficiency of B cells, indicating the par-
ticipation of PU.1 in both osteoclastogenesis and B lym-
phopoiesis (McKercher et al., 1996; Tondravi et al., 1997). 
B cell lymphoma 6 (Bcl-6) is required by germinal center B 
cells to escape from the fate of apoptosis induced by DNA 
damage; to maintain self-renewal and survival; and to allow  
1244 Zhao, L., et al.   Sci China Life Sci   December (2016) Vol.59 No.12 
Table 1  Genetically modified animal models displaying a reciprocal interaction between immune cells and bone remodelinga) 
Mouse model Function of the modified gene/molecule Bone remodeling phe-
notype 
Influence on immune cells and HSCs Reference 
RANK-Tg RANK: binds with RANKL, activates NF-B 
via intracellular signaling cascade transduction 
and induces OC differentiation and maturation 
Osteoporosis Enlarged cutaneous lymph nodes (Hess et al., 2012) 
RANK/ Same as above Osteopetrosis; 
tooth loss 
B cell deficiency and abnormal B com 
partment; 
lack of peripheral lymph nodes 
(Dougall et al., 1999; 
Marrella et al., 2015) 
RANKL-Tg RANKL: binds to RANK and stimulates OC
formation 
Osteoporosis Increased mTEC cells and enlarged  
thymic medulla 
(Ohigashi et al., 
 2011) 
RANKL/ Same as above Osteopetrosis; 
tooth loss 
Defective differentiation of early T/B  
lymphocytes; 
lack of peripheral lymph nodes; 
shrinking thymus 
(Kong et al., 1999b) 
OPG-Tg OPG: decoy receptor for RANKL; prevents
RANKL-induced bone absorption and induces
monocytes chemotaxis and adhesion 
Osteopetrosis Extramedullary hematopoiesis (Simonet et al., 1997; 
Stolina et al., 2007) 
OPG/ Same as above Osteoporosis Induction of monocyte chemotaxis and 
promotion of monocyte adhesion 
(Bucay et al., 1998; 
Mizuno et al., 1998) 
c-Fos/ c-Fos: component of activator protein 1; essen-
tial for OC differentiation 
Osteopetrosis Reduced B cell number in the spleen and 
increased CD4+ or CD8+ thymocyte 
number but reduced number of dou-
ble-positive T cells 
(Okada et al., 1994; 
Wang et al., 1992) 
TRAF6/ TRAF6: intracellular adaptor protein Osteopetrosis; 
Tooth eruption 
Impaired response to LPS; 
impaired B cell proliferation in response 
to CD40 and LPS induction 
(Lomaga et al., 1999) 
Pax5/ Pax5: helps to maintain B lineage commitment 
and regulates transition from proB to preB 
Osteopenia ProB accumulation; 
lack of following stage of B cells 
(Horowitz et al.,  
2004; Nutt et al.,  
1999) 
PU.1/ PU.1: involved in B cell and myeloid lineage 
development 
Osteopetrosis Absence of B cells and macrophages (McKercher et al.,  
1996; Tondravi et al., 
1997) 
Bcl-6/ Bcl-6: involved in B cell self-renewal and  
proliferation, forming diverse polyclonal B cell 
repertoire 
Osteoporosis Reduced number of new immature B 
cells and decreased clonal diversity 
(Duy et al., 2010;  
Miyauchi et al., 2010) 
DAP12/ DAP12: intracellular adaptor protein bearing  
ITAM 
Osteopetrosis Arrest of B development at pro-preB 
stage 
(Despars et al., 2013) 
OPN/ OPN: involved in cell adhesion, angiogenesis,  





Reduced Th1 response; 
increased HSC proliferation 
(Nilsson et al., 2005), 




NF-B: dimer composed of various combina-
tions of p50, p52, p65, c-Rel and RelB; serves
as a critical transcription factor and participates 
in host defense 
Osteopetrosis Impaired B cell development and matu-
ration; 
defective thymic architecture 
(Franzoso et al.,  
1997) 
a) HSCs, hematopoietic stem cells; Tg, transgenic; /, knockout; RANK, receptor activator of nuclear factor-kappa B; RANKL, RANK ligand; OPG, 
osteoprotegerin; TRAF6, tumor necrosis factor receptor-associated factor 6; Bcl-6, B cell lymphoma 6; OPN, osteopontin; mTEC, medullary thymic epithe-
lial cell. 
formation of a normal, diverse polyclonal repertoire (Duy et 
al., 2010). Bcl-6 can also facilitate osteoblastogenesis by 
recuperating the Runx2 nuclear translocation inhibited by 
STAT1 and can suppress osteoclastogenesis by attenuating 
NFATc1 target gene transcription (Fujie et al., 2015; 
Miyauchi et al., 2010). Bcl-6/ mice exhibit a distinct OP 
phenotype, with a markedly reduced new immature B cell 
pool in the bone marrow and impaired clonal diversity (Duy 
et al., 2010; Miyauchi et al., 2010). Finally, DNAX-    
activating protein 12 (DAP12) is a transmembrane immu-
noreceptor tyrosine-based activation motif (ITAM)- 
bearing adaptor protein; ITAM signaling is critical in regu-
lating the innate immune response and adaptive immune 
cell function as well as OC differentiation. DAP12-deficient 
mice display interrupted immature B cell development at 
the pro-preB stage and an impaired immune response, along 
with a distinct osteopetrosis phenotype (Despars et al., 
2013; Hamerman et al., 2005).  
RANK/RANKL/OPG triad bridges bone remodel-
ing and immune response   
RANK/RANKL/OPG signaling in bone remodeling 
The receptor activator of nuclear factor-kappa B (RANK)/ 
RANK ligand (RANKL)/osteoprotegerin (OPG) axis is of 
paramount importance both in physiological bone remodel-
ing and in pathological bone destruction (Theill et al., 
2002). This triad is critical in the communication between 
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the skeletal system and the immune system. 
RANKL, RANK and OPG all belong to the tumor necro-
sis factor (TNF)/TNF receptor (TNFR) superfamily and 
were discovered during 1996–1997 (Anderson et al., 1997; 
Lacey et al., 1998; Nakagawa et al., 1998; Wong et al., 
1997a; Yasuda et al., 1998). RANKL, also known as 
TNFSF11, is reported to be expressed by activated T cells, 
T cells, B cells and natural killer cells as well as OBs, 
osteocytes and fibroblasts (Horwood, 2013). Expression of 
RANK has been reported in macrophages, dendritic cells 
(DCs), monocytes and OCs. The interaction of RANKL 
with RANK not only can enhance DC survival and promote 
cytokine production and T cell-DC interaction but also can 
contribute to osteoclastogenesis and OC activation; thus, 
Rankl knockout (Rankl/) mice are defective in OC priming 
and are prone to osteopetrosis (Odgren et al., 2003). People 
with RANKL gene mutation have been reported to suffer 
from autosomal recessive osteopetrosis, with func-
tion-defective OCs (Sobacchi et al., 2007), whereas trans-
genic over-expression of RANKL in T cells rescues OC 
development and restores the bone marrow cavity in 
Rankl/ mice, indicating that T cells can regulate bone me-
tabolism through the RANKL pathway (Kim et al., 2000). 
RANK-RANKL signaling is generally accepted as the key 
pathway responsible for osteoclastogenesis and inflamma-
tion-mediated bone destruction. Although how signal 
transduction following RANK-RANKL conjugation 
switches on the bone resorption machinery in OCs remains 
to be elucidated, certain intermediate processes have been 
proposed. 
Macrophage colony-stimulating factor (M-CSF) plays a 
critical role in inducing OCs proliferation and survival. And 
via binding to RANK on OCs with surface RANKL, OBs, 
osteocytes and activated T cells regulate OCs differentiation 
and mediate osteoclastogenesis (Xiong et al., 2015). The 
intracellular domain of RANK contains three cytoplasmic 
tumor necrosis factor receptor associated factor 
(TRAF)-binding motifs that can recruit TRAF1, TRAF2, 
TRAF3, TRAF5, and TRAF6. TRAF6 is particularly essen-
tial in mediating RANK-induced nuclear factor-kappa B 
(NF-B) activation and inducing NFATc1 expression 
(Darnay et al., 1999). The role of NF-B in OCs develop-
ment and bone resorption has been intensely investigated 
and reviewed (Abu-Amer, 2013). TRAF6 recruitment se-
quentially induces the activation of downstream signaling 
cascades, including NF-B, c-Fos, extracellular signal- 
regulated kinase (ERK), c-Src, and c-Jun NH2-terminal 
kinase (JNK) signaling (Wong et al., 1997b), all of which 
contribute to NFATc1 activation and amplification. The 
transcription factor NFATc1 is primed to directly regulate 
the expression of osteoclastogenic genes, including TRAP, 
cathepsin K,  integrin and the calcitonin receptor, and then 
promote the differentiation, proliferation, morphogenesis 
and activation of OCs (Arron and Choi, 2000; Darnay et al., 
1998, 1999; Ikeda et al., 2004; Kobayashi et al., 2001; 
Wong et al., 1999a). 
What’s more, co-stimulatory immunoglobulin (Ig) like 
receptors: OSCAR (osteoclast-associated receptor) and 
TREM2 (triggering receptor expressed on myeloid cells-2) 
are associated with ITAM-containing adaptor molecules— 
Fc receptor common  unit (FcR) and DAP12 respectively, 
and RANK activation leads to the phosphorylation of ITAM 
and then activate calcium ions signaling which also contrib-
utes to NFATc1 priming (Takayanagi, 2009).  
The interaction of RANK and RANKL can be impeded 
by the naturally occurring decoy receptor OPG, which is 
produced by stromal cells, B lymphocytes and DCs. OPG 
competes with RANK for RANKL binding with a higher 
affinity and is capable of blocking signal transduction 
downstream of RANK and inhibiting OC development and 
activation. OPG can prevent bone loss and act as a bone 
protector, as its name implies. OPG-transgenic mice exhibit 
osteopetrosis and decreased OC numbers, along with ex-
tramedullary hematopoiesis (Simonet et al., 1997; Stolina et 
al., 2007). In contrast, OPG-deficient mice show severe OP 
and are prone to bone fracture (Bucay et al., 1998; Mizuno 
et al., 1998). As estrogen promotes OPG production by 
OBs, OP in postmenopausal women develops partly due to 
reduced estrogen. The RANK/RANKL/OPG triad is the 
critical vinculum bridging the immune response and bone 
metabolism. In particular, activated T cells are capable of 
inducing morphological maturation and functional activa-
tion of OCs and triggering bone absorption through surface 
RANK. The triad also participates in the cardiovascular, 
endocrine and nervous systems and plays a critical role in 
malignant bone metastases, but these topics are outside the 
focus of this review. 
Role of RANK/RANKL/OPG in lymphoid organogenesis and 
immune response 
RANKL was first cloned in T cells and is widely accepted 
to be important in T/B lymphocyte development and DC 
survival. The RANK-RANKL interaction can promote 
CD40 expression, and the ligation of CD40 with CD40 lig-
and (CD40L), which in turn up-regulates OPG expression 
on follicular DCs (Yun et al., 1998). Coordinating with oth-
er cytokines, RANK/RANKL/OPG orchestrates tuning of 
the immune response by priming T cell activation, regulat-
ing T cell-DC communication, promoting DC survival and 
participating in lymph node (LN) organogenesis (Anderson 
et al., 1997; Wong et al., 1997a).  
LN organogenesis 
Comprehensive expression of RANKL on multiple immune 
tissues, including the LNs, spleen, thymus and intestinal 
Peyer’s patches, suggests its possible influence on second-
ary lymphoid organ development and organization. 
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RANK/, RANKL/ and TRAF6/ mice exhibit com-
pletely absent LNs and smaller Peyer’s patches but an intact 
spleen, suggesting a specific and essential role of the 
RANK/RANKL/OPG triad in LN organogenesis (Dougall 
et al., 1999; Kong et al., 1999b). It is postulated that 
RANK-RANKL signaling may act as a growth and survival 
mediator in the early development of LNs by recruiting 
lymphopoietic precursors and stimulating the proliferation 
of stromal cells. When coupled with lymphotoxin (LT)-LT 
receptor (LTR) signaling, the RANK-RANKL signal 
forms an important positive feedback loop between lym-
phoid tissue organizer (LTo) cells, which are of mesenchy-
mal origin, and lymphoid tissue inducer (LTi) cells, which 
are of hematopoietic origin (Mueller and Hess, 2012). LTi 
cells express RANK, RANKL and LT. RANK on LTi cells 
is triggered by interaction with RANKL-bearing LTi cells 
and leads to enhanced production of LT. Binding of 
LT with its receptor LTR on LTo cells in turn induces 
more RANKL production (Mueller and Hess, 2012; 
Roozendaal and Mebius, 2011). This self-amplification 
feedback results in abundant synthesis of chemokines such 
as CXCL13 and adhesion molecules such as intracellular 
adhesion molecule 1 (ICAM-1), vascular adhesion molecule 
1 (VCAM-1) and mucosal addressin cell adhesion molecule 
1 (MAdCAM-1). These molecules help to attract and retain 
more LTi cells in the LNs and give rise to functional LN 
establishment (Koning and Mebius, 2012). Moreover, 
RANK-transgenic mice display hyperplastic LNs, with pro-
liferated vascular and reticular fibroblastic stromal cells 
(Hess et al., 2012). Thus, RANK-RANKL signaling con-
tributes to the development of LNs by boosting both lym-
phopoietic and MSC accumulation. 
Innate immune response 
Mice injected with lipopolysaccharide (LPS) show down- 
regulated RANKL and up-regulated OPG. RANKL pre-
treatment induces macrophage tolerance to bacterial im-
munization in these mice by suppressing inflammatory cy-
tokine production, protecting the mice from LPS-induced 
death (Maruyama et al., 2006). For Tnfsf11/ mice, which 
lack RANKL, LPS stimulation can potentiate increased re-
lease of TNF- and IL-6, and elevated lethality can be ob-
served. Conversely, Tnfrsf11b/ mice, which lack OPG but 
have a higher serum level of RANKL, exhibit impaired 
production of IL-6 in response to LPS stimulation 
(Maruyama et al., 2006). Toll-like receptors (TLRs) have 
been reported to promote OC formation by up-regulating 
RANKL expression on fibroblast-like synoviocytes in RA 
(Kassem et al., 2015; Kim et al., 2007a, 2009). However, 
TLRs have also been reported to be capable of inhibiting 
osteoclastogenesis and limiting the pathological bone loss 
associated with inflammation through inhibition of RANK 
expression in cooperation with interferon (IFN)- (Ji et al., 
2009).  
Interaction of immune cells and bone cells 
Interaction of T cells and bone cells 
T cells play a dual role in bone remodeling. Resting T cells 
potentiate bone protection, probably by inducing OPG pro-
duction via CD40L costimulation. T cell-depleted mice ex-
perience decreased bone density and increased OC numbers 
(Li et al., 2007). Meanwhile, activated T cells up-regulate 
surface RANKL expression to enhance OC development 
and participate in inflammation-associated OP (Kong et al., 
1999a). A protective self-induced countermeasure mecha-
nism against activated T cells mediated osteoclastogenesis 
under physiological conditions has been proposed by Taka-
yanagi et al. (Takayanagi et al., 2000). They discovered that 
IFN- secreted by inflammatory T cells is capable of acti-
vating the ubiquitin-proteasome pathway and leading to 
rapid TRAF6 degradation. This counterbalances enhanced 
RANKL expression and suppresses OC development. Ifnr/ 
mice develop accelerated bone destruction compared with 
wild-type mice when experiencing collagen-induced in-
flammatory arthritis, which provides further evidence for 
this protective mechanism. Not all activated T cells are os-
teoclastogenesis promoters. Th1 and Th2 cells are reported 
to inhibit osteoclastogenesis by secreting IFN- and IL-4, 
whereas Th17 cells facilitate osteoclastogenesis through 
their own surface RANKL expression and IL-17-mediated 
RANKL expression on supporting cells (Sato et al., 2006). 
By recruiting other inflammatory cells and promoting the 
release of inflammatory cytokines such as TNF- and IL-1, 
Th17 cells polarize the microenvironment in favor of OC 
development. Il17/ mice of arthritis model and mice with 
collagen-induced arthritis (CIA) that are injected with a 
neutralizing antibody against IL-17 are protected from bone 
destruction (Lubberts et al., 2004; Nakae et al., 2003). In 
addition, IL-17F released by Th17 cells during bone frac-
ture is a pivotal cytokine in promoting OB maturation and 
bone healing (Nam et al., 2012). Other cytokines released 
from T cells during inflammation may be able to interfere 
with OC formation, e.g., IL-12 alone or in synergy with 
IL-18 can potently inhibit RANKL-induced OC formation 
in vitro, probably by driving Th1 development and IFN- 
signaling (Horwood et al., 2001). 
Although poorly defined and lacking sufficient evidence, 
T cells may play a role in osteoblastogenesis by coupled 
up-regulated bone turnover. Rifas et al. deduced that in-
creased alkaline phosphatase activity in bone marrow stro-
mal cells (BMSCs) and elevated mRNA expression of 
Runx2 and osteocalcin by soluble factors released from T 
cells indicate the capacity of T cells in inducing OB differ-
entiation (Rifas et al., 2003). Regulatory T cells (Treg) have 
been shown to be capable of directly affecting bone biology 
and effectively preventing the local bone destruction and 
systemic bone loss induced by TNF- (Zaiss et al., 2010a). 
Foxp3-transgenic mice are protected from ovariectomy- 
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induced OP via impaired OC differentiation (Zaiss et al., 
2010b), and activated Treg transfer has been reported to 
improve the clinical outcome in CIA mice and to inhibit OC 
differentiation both in vitro and in vivo (Kelchtermans et al., 
2009). It is supposed that Treg suppress osteoclastogenesis 
by cell-cell contact via cytotoxic T-lymphocyte antigen 4 
(CTLA4) and by secretion of transforming growth factor 
(TGF)-, IL-4 and IL-10 (Kim et al., 2007b; Zaiss et al., 
2007). Yet it’s worthy of notice that Treg cells possess plas-
ticity and pathogenic Th17 cells could originate from Treg. 
Those IL-17+Foxp3+T cells are found accumulating in the 
synovium of inflamed joints of patients with RA and are 
thought as potent osteoclastogenic and arthritogenic T cells 
expressing RANKL. Contrary to the anti-inflammatory ef-
fect of classic Treg, IL-17+Foxp3+T cells are “inflammatory 
Treg” which may be the product of imbalanced cytokines 
status and intense contest between autoimmunity and 
self-tolerance (Komatsu et al., 2014). Anyway, anti-TNF- 
therapy can restore Treg function via increased Foxp3 
phosphorylation and adjust the balance between Treg and 
Th17 cells (Nie et al., 2013), to which its effectiveness in 
RA can be partly owing. Modulating Treg development and 
increasing Treg numbers may therefore be a promising 
therapeutic strategy in diseases associated with over- 
activated OCs and accelerated bone loss.  
The RANK/RANKL/OPG triad is of great importance in 
T cell development. T cell negative selection and Foxp3+ 
Treg emergence in the thymus are dependent on the medul-
lary thymic epithelial cell (mTEC) compartment and the 
thymic medullary microenvironment (Aschenbrenner et al., 
2007; Hikosaka et al., 2008; Ohigashi et al., 2011). mTECs 
present self-antigens, participate in establishing T cell cen-
tral tolerance checkpoints and contribute to autoreactive T 
cell clonal deletion in the thymus. RANK, OPG, CD40, and 
LTR expressed on mTECs cooperate to promote mTEC 
development and help to establish and maintain the homeo-
stasis of the thymic medullary microenvironment (Akiyama 
et al., 2008). Rankl/ mice exhibit blocked differentiation 
from CD25+CD44 to CD25CD44 thymocytes and re-
duced thymic cellularity (Kong et al., 1999b). Similar pro-
gression defects can also be observed in OPG-transgenic 
mice and recombinant-OPG-treated mice (Stolina et al., 
2007).Th1 cytokines produced by rankl/ T cells are sig-
nificantly reduced under stimulation with anti-CD3/anti- 
CD28 and cannot be restored by exogenous RANKL (Kong 
et al., 1999b). In contrast, RANKL-transgenic mice display 
increased mTEC numbers and an enlarged thymic medulla, 
indicating the regulatory function of the RANK-RANK- 
OPG signal in the early development of T cells. RANKL 
signaling in the thymus influences the intrathymic Treg pool 
by enhancing peripheral Treg recirculation back to the thy-
mus (McCarthy et al., 2015). OCs have been reported to be 
capable of inducing T cell activation and proliferation as 
well as supporting T cell survival in vitro, mainly through 
a TNF--mediated pathway or direct cell-cell contact 
(Pappalardo and Thompson, 2015). Conversely, activated 
T cells negatively regulate OC formation by secreting 
IFN- (Pappalardo and Thompson, 2013).  
Interaction of B cells and bone cells 
The B cell lineage has a profound reciprocal interaction 
with the bone system (Manilay and Zouali, 2014). B 
cell-produced OPG has been proven to be an important reg-
ulator in bone metabolism (Li et al., 2007), and this produc-
tion can be augmented by T cells via CD40-CD40L costim-
ulation (Yun et al., 1998). B cell depletion in mice leads to 
significantly decreased OPG and increased bone resorption, 
which can be rescued by B cell reconstitution. This finding 
is of certain physiopathological importance in protecting 
bone against damage when confronted with infection and 
inflammation. Meanwhile, B cells are also a source of 
RANKL, thus playing a role in shaping OC development. 
Under certain pathological conditions, RANKL produced 
by B cells may neutralize or overwhelm B cell-derived 
OPG, resulting in accelerated bone loss. In vitro, activated 
B cells can promote the development and maturation of 
OCs by producing multiple cytokines (Choi et al., 2001). 
The IgG immune complex (IgG-IC) comprehensively regu-
lates the immune response through FcR signaling, but 
meanwhile is also a potent stimulator of OC formation. 
High titers of IgG in CIA mice strongly promote osteoclas-
togenesis, which can be abrogated by depleting IgG in the 
serum. Negishi-Koga et al. have recently reported that the 
engagement of FcRs provides costimulatory signals for 
osteoclastogenesis (Negishi-Koga et al., 2015). IgG-IC- 
FcR signaling participates in OC expansion and bone ho-
meostasis breakdown. FcRIIB and FcRIII are negative 
modulators of osteoclastogenesis, with a mechanism of 
competitive occupation, depleting the availability of FcR 
to other activating ligands. Temporary down-regulation of 
FcRIII is a necessary physiological process during OC 
differentiation (Negishi-Koga et al., 2015). Harre et al. fur-
ther verified that desialylated IgG-ICs with enhanced bind-
ing and engagement of FcRs could be more favorable for 
driving osteoclastogenesis (Harre et al., 2015). 
B cell commitment and maturation are dependent on 
cell-cell contact with OBs (Zhu et al., 2007), while OCs can 
support the survival of plasma cells independent of B lym-
phocyte stimulation through cell-cell contact (Geffroy- 
Luseau et al., 2008). Absence of preB and proB cells in 
Col2.3Δ-TK-transgenic mice after selective depletion of 
OBs confirmed the role of OBs in B cell lymphopoiesis 
(Zhu et al., 2007). OB-derived RANKL is essential for preB 
cells to develop into mature B cells, and pre-B cells exhibit 
arrested development in rankl/ mice (Zhu et al., 2007). But 
the role of the RANK-RANKL axis in B cell physiology is 
far more sophisticated and still a matter of debate. Recently, 
rankl/ mice are found to exhibit relative expansion of 
1248 Zhao, L., et al.   Sci China Life Sci   December (2016) Vol.59 No.12 
marginal zone B cells and plasma cells, increased Ig secre-
tion and spontaneous germinal center formation, which may 
be attributed to increased regulatory B cell numbers and 
enhanced IL-10 production (Marrella et al., 2015). Both 
OBs and multipotent stromal cells are the main sources of 
stromal cell-derived factor 1 (SDF-1), IL-7 and CXCL12, 
which collaborate to construct indispensable niches for B 
cell development (Woodward, 2010; Wu et al., 2008; Zhu et 
al., 2007). OPG/ mice have been reported to have accu-
mulated transitional B cells in the spleen, enhanced B cell 
proliferation under IL-7 stimulation, and compromised Ig 
switching in response to T cell-dependent antigen (Yun et 
al., 2001). Paradoxically, OPG-transgenic mice exhibit no 
significant functional alterations in humoral immune re-
sponses (Stolina et al., 2007). However, elimination of 
functional RANKL or RANK reveals dramatically defective 
B cell development and hypogammaglobulinemia both in 
mice and in humans, which may mainly be due to osteo-
petrosis and a shrinking bone marrow cavity (Guerrini et al., 
2008; Kong et al., 1999b).    
Interaction of DCs and bone cells 
DCs are highly differentiated antigen-presenting cells with 
the plasticity to transdifferentiate into OCs under appropri-
ate stimulation (e.g., in the presence of M-CSF and 
RANKL) (Alnaeeli et al., 2006; Rivollier et al., 2004). 
RANKL is capable of protecting DCs from Fas lig-
and-induced apoptosis (Chen et al., 2004). The synergy of 
RANKL and CD40L, which are both expressed by activated 
T cells, controls DC survival and stimulates proinflamma- 
tory cytokine production by DCs (Josien et al., 1999, 2000). 
Similar features can be observed in OPG/ mice (Chino et 
al., 2009; Wong et al., 1999b). RA provides a microenvi-
ronment in the synovium and synovial fluid that is abundant 
in pro-inflammatory cytokines capable of supporting trans-
differentiation. DC-derived OCs have been suggested to be 
involved in osteolytic lesions (Santiago-Schwarz et al., 
2001). DCs can also act as OB precursors, and T cell-DC 
interaction may directly contribute (Alnaeeli et al., 2006) to 
osteoclastogenesis in a RANKL-dependent manner (Page 
and Miossec, 2005). Considering the important role of DCs 
in immune response initiation and perpetuation as well as 
their status as efficient inducers of Th17 cells (Dhodapkar et 
al., 2008), DCs are important mediators of inflamma-
tion-associated bone loss and provide a promising therapeu-
tic target for modulating inflammatory bone destruction 
(Alnaeeli et al., 2007). 
Role of cytokines in bone homeostasis  
Multiple cytokines and factors are involved in the complex 
bone homeostasis regulatory network, especially during 
rheumatic bone erosion, which has been reviewed in litera-
ture (Arboleya and Castaneda, 2013) and is also summa-
rized in Table 2. 
M-CSF 
M-CSF is a critical growth stimulator for the macrophage 
lineage and OC progenitors. In the spontaneous-mutant os-
teopetrotic mouse strain op/op, decreased OC numbers cou-
pled with impaired bone resorption and defective M-CSF 
production are key characteristics (Felix et al., 1990b). 
Op/op mice are specifically deficient in M-CSF and exhibit 
osteopetrosis. Replenishment with recombinant M-CSF can 
induce OC formation and restore the bone marrow cavity 
that is absent in op/op mice (Felix et al., 1990a). M-CSF 
stimulates RANK expression in OC precursors, promotes 
OC differentiation and prolongs OC survival in vivo (Fuller 
et al., 1993) and is indispensable for inducing OC formation 
from monocytes/macrophages in vitro (Marino et al., 2014).  
TNF- 
TNF- can enhance RANKL expression on OBs and 
M-CSF production by stromal cells, can augment the re-
sponsiveness of OC precursors to RANKL and can stimu-
late OC maturation. Moreover, TNF- can induce the ex-
pression of OSCAR, which in turn costimulates OC for-
mation. By modulating Wnt signaling activation, inhibiting 
the expression of the transcription factor Runx2 and 
up-regulating the RANKL/OPG ratio, TNF- suppresses 
OB differentiation while promoting OC maturation. In the 
presence of M-CSF, TNF- coupling with IL-1 can induce 
mouse bone marrow macrophages to develop into TRAR+ 
OCs (Yamashita et al., 2015; Zhang et al., 2001). Flourish-
ing clinical application of TNF- blockers in RA and other 
types of inflammatory arthritis has yielded inspiring thera-
peutic effects in preventing progressive bone destruction, 
even reversing bone erosion.  
IL-1 
IL-1 is another potent osteoclastogenesis inducer produced 
by macrophages, MSC and lymphocytes. IL-1 is capable of 
up-regulating RANKL expression on BMSCs and inducing 
OC precursors to differentiate into mature OCs as well as 
prolonging OC survival and enhancing OC bone-absorbing 
activity. TNF- can induce IL-1 production, coordinate 
with IL-1 and depend on IL-1 to mediate OC activation and 
promote inflammation-associated bone loss (Wei et al., 
2005). Bone loss induced by estrogen deficiency occurs 
partly via IL-1, and blockade of IL-1 can prevent bone loss 
both in postmenopausal women and in ovariectomized 
mice. 
IFN- 
IFN- abrogates the signaling transduction downstream of 
RANKL and rescues OP in ovariectomized mice (Duque et 
al., 2011; Takayanagi et al., 2000). IFN- also plays a role 
in osteoblastogenesis by promoting the differentiation of 
MSC into OBs (Duque et al., 2009). And by mediating  
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Table 2  Cytokines involved in bone remodeling and the immune responsea) 
Cytokine Source Effect on OBs/OCs Effect on immunity 
TNF- Th1, macrophage, DC OB formation↓/↑; 
OC formation↑; Pro-inflammation 
IFN- Th1, natural killer cell 
OB formation↑; 
OC formation↓/↑ 
(depends on context) 
Cellular immunity 
IL-12 Macrophage, DC OC formation↓ Th1 cell differentiation; 
IFN- and GM-CSF induction 
IL-18 Macrophage, DC OC formation↓ Th1 cell differentiation, IFN- induction 
GM-CSF Th1 OC formation↓ Macrophage recruitment; pro-inflammation 
IL-4 Th2 OC formation↓ Humoral immunity 
IL-6 
Macrophage, DC, 
Th2 synovial fibroblast 
OC formation↑ Pro-inflammation; Th17 induction 
IL-10 Th2, Treg OC formation↓ Anti-inflammation 
IL-17 Th17, T OB formation↓; 
OC formation↑ Pro-inflammation 
IL-23 Macrophage, DC OC formation↑ Th17 induction 
IL-1 Macrophage, DC OC formation↑ Pro-inflammation 
TGF- Treg, OB, BMSC OC apoptosis↑ Anti-inflammation, involved in Th17/Treg dif-ferentiation 
OSM OB, OC, macrophage, T cell 
OB formation and mineralization↑; 
OC formation↑ 
(pathological condition) 
Induction of megakaryocyte hematopoiesis 
IL-7 BMSC OC formation↑ Promotion of T/B cell development 
IL-27 Macrophage, DC OC formation↓ Th1 and Treg↑; Th17 induction 
a) DCs, dendritic cells; OSM, oncostatin M. Treg, regulatory T cell; Th17, IL-17 secreting T cell; BMSC, bone marrow stromal cell 
rapid TRAF6 degradation via activating ubiquitin- 
proteasome, IFN- suppresses OC development and acting 
as a bone-protective factor. But IFN- can also act as a 
pro-absorptive cytokine by stimulating antigen-dependent T 
activation and promoting T cell secretion of TNF- and 
RANKL (Gao et al., 2007). Therefore, the paradoxical role 
of IFN- in bone remodeling involves directly targeting OC 
precursors to inhibit osteoclastogenesis and indirectly stim-
ulating OC formation to facilitate osteoclastogenesis. The 
influence of IFN- on bone homeostasis is dependent on the 
net effects in different contexts. 
IL-4 
IL-4 is a pleiotropic cytokine that has also been found to be 
a potent negative regulator of OC formation and OC activa-
tion through inhibiting NFATc1 and c-Fos expression, in-
ducing OPG production and attenuating RANKL and 
RANK expression via a mechanism depending on 
STAT6-mediated NF-B signaling inhibition (Abu-Amer, 
2001; Moreno et al., 2003; Palmqvist et al., 2006; Yamada 
et al., 2007). 
IL-10 
In bone remodeling, synthesis of bone proteins (e.g., alka-
line phosphatase, collagen and osteocalcin) and mineraliza-
tion of extracellular matrix can be suppressed by IL-10. 
Additionally, by inhibiting the intranuclear translocation of 
NFATc1, IL-10 can prevent RANKL-mediated osteoclas-
togenesis at an early stage (Evans and Fox, 2007; Mohamed 
et al., 2007). IL-10/ mice thus develop an osteopenic phe-
notype with increased bone fragility (Dresner-Pollak et al., 
2004).  
IL-6 
IL-6, produced by macrophages, DCs and BMSCs, is a po-
tent stimulator of OC activation and bone absorption via 
RANKL up-regulation. In synergy with TNF-, IL-6 plays 
a pivotal role in the synovitis with pannus formation and 
contributes to the pathogenesis of RA. Blockade of IL-6 
ameliorates the osteoclastogenesis induced by active RA 
sera in vitro (Pathak et al., 2014) and suppresses joint de-
struction in FcRIIB-deficient RA mice (Ohtsuji et al., 
2015).   
IL-17 
Th17 cells are IL-17-secreting cells with robust RANKL 
expression and vigorous pro-inflammatory potency 
(Takayanagi, 2009). IL-17 has been shown to synergistical-
ly induce RANK expression on OC precursors and promote 
RANKL expression on OBs, BMSCs and synovial fibro-
blasts, thus supporting OC development (Adamopoulos and 
Bowman, 2008; Adamopoulos et al., 2010). IL-17 is also 
thought to play a critical role in progressive periodontitis 
(PD) and erosive arthritis. Neutralizing IL-17 in CIA mice 
therefore helps to reduce joint inflammation, cartilage de-
struction and bone erosion. 
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TGF- 
TGF- positively modulates bone formation by inducing 
OB precursor differentiation and migration and abrogating 
OB apoptosis, possibly by enhancing Runx2 expression 
(Lee et al., 2000). However, in the later stage of OB matu-
ration, TGF-1 inhibits the proliferation and mineralization 
of OBs in accordance with Runx2 suppression (Alliston et 
al., 2001; Kang et al., 2005). 
Oncostatin M (OSM) 
OSM is a pleiotropic cytokine belonging to the IL-6 family 
that influences both bone formation and bone resorption. 
Irrespective of its role in malignancy, OSM, produced by 
cells of hematopoietic origin (e.g., T lymphocytes and 
macrophages) and mesenchymal origin (e.g., OBs and os-
teocytes) in the bone marrow microenvironment, can con-
trol both OB and OC formation. In particular, OSM pro-
motes OB differentiation and directs stromal cells to OB 
commitment. OSM is also capable of inducing RANKL 
expression on OBs to drive osteoclastogenesis and has the 
potential to contribute to bone destruction in inflammatory 
arthritis and bone metastasis in combination with IL-1 and 
TNF- (Bolin et al., 2012; Hui et al., 2005; Le Goff et al., 
2014). Therefore, OSM exerts both anabolic and catabolic 
effects on bones and participates in pathological bone de-
struction and new periosteal bone formation.   
OPN 
OPN is a cytokine with pleiotropic properties that is synthe-
sized by multiple cell types, including immune cells such as 
DCs and T/B lymphocytes and bone cells such as OBs. 
OPN plays a role in bone remodeling, modulates minerali-
zation of the skeleton and participates in absorption of min-
eralized bone by anchoring OCs onto the bone surface and 
stimulating interaction of OCs and stromal cells (Denhardt 
et al., 2001; Heinegard et al., 1995). OPN is also involved in 
regulating the immune response to injury; infection; and 
auto-inflammatory disease, such as RA, via integrins and 
CD44 (Xu et al., 2005). Although not indispensable, OPN 
modulates cell-mediated responses by promoting the Th1 
response, as indicated by an abrogated Th1 response in 
OPN/ mice, and is also capable of supporting Th17 and B 
cell differentiation (Rittling and Singh, 2015) as well as 
influencing IFN-, IL-10 and IL-12 production (Ashkar et 
al., 2000). 
Complement 
The complement system serves as an important component 
of innate immunity by opsonizing antigens, mediating 
phagocytosis, modulating cell migration and apoptosis, in-
ducing cytokine release and promoting the inflammatory 
reaction, thus playing a critical role in defense against inva-
sive microorganisms and in clearance of cellular debris of 
self-origin (Zipfel and Skerka, 2009). Evidence shows that 
the complement system also plays a role in bone biology. 
For example, modulation of complement C3a and C5a have 
been reported to modulate OB formation and OC activation 
(Ignatius et al., 2011), and reduction of C3aR/C5aR activity 
inhibits OC generation (Tu et al., 2010). In addition, 
OC-derived C3a stimulates OB differentiation (Matsuoka et 
al., 2014). In synergy with IL-1, under pro-inflammatory 
conditions, C3a and C5a are capable of inducing IL-6 and 
IL-8 release from OBs and up-regulating RANKL/OPG 
expression, culminating in the inflammatory phenotype of 
OBs (Ignatius et al., 2011), which represents bidirectional 
communication between OCs and OBs. 
CLINICAL DISEASES ASSOCIATED WITH 
OSTEOIMMUNOLOGY 
RA (rheumatoid arthritis) 
RA is a typical disorder for demonstrating the connotations 
of osteoimmunology. Specifically, RA is an autoim-
mune-mediated chronic inflammatory arthritis with high 
morbidity and a high rate of crippling. Synovial pannus, 
juxta-articular osteopenia, and erosion of the cartilage and 
subchondral bone are the pathological characteristics of RA. 
Increased levels of activated OCs are the predominant dis-
turbance of bone homeostasis that occurs, and exaggerated 
levels of pro-inflammatory cytokines, including IL-1, TNF 
and IL-6, are remarkable both in affected joints and in the 
peripheral serum (Le Goff et al., 2013). Augmented 
RANKL expression in RA synovium by synovial fibroblasts 
and activated T cells has also been found (Gravallese et al., 
2000). It has been confirmed that synovial fluid mononu-
clear cells in flamed joints have the potential to spontane-
ously develop into functional OCs ex vivo, which is further 
augmented in the presence of RANKL and M-CSF (Greisen 
et al., 2015). Bone loss and erosion in RA are mainly at-
tributed to enhanced RANKL expression on activated syno-
vial fibroblasts; infiltrative mononuclear cells; and activated 
T cells, and especially Th17 cells from RA tissue. The con-
centration of soluble RANKL, which is probably derived 
from T cells, is comparatively higher than that of OPG in 
the synovial fluid in RA patients (Kotake et al., 2001). 
RANKL-loaded activated T cells can directly trigger osteo-
clastogenesis, leading to OC amplification and bone loss. 
However, this pro-osteoclastogenic effect may be partly 
counterbalanced by IFN- secreted by activated T cells 
themselves. Peripheral blood monocytes and synovial mac-
rophages have the potentiality of differentiating into OCs in 
certain microenvironments (e.g., in the presence of M-CSF 
and 1,25(OH)2 vitamin D3) (Fujikawa et al., 1996a, b; 
Takayanagi et al., 1997), which may serve as a critical 
mechanism of bone destruction in RA. In a mouse model, 
OPG treatment at disease onset could abolish bone matrix 
degeneration, inhibit OCs accumulation and prevent carti-
lage destruction and joint crippling (Kong et al., 1999a). 
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The crucial role of cytokines central to the pathogenesis of 
RA has been reviewed in detail in the literature (McInnes 
and Schett, 2007). 
Anti-citrullinated peptide antibody (ACPA) is a dis-
ease-specific antibody with potent pathogenicity for RA via 
its pro-osteoclastogenic effect. During OC differentiation, 
specific N-terminal vimentin citrullination is induced. AC-
PAs can bind to the OC surface, leading to TNF- release 
from OC precursors and stimulating robust osteoclastogen-
esis and bone absorptive activity (Harre et al., 2012). High 
titers of ACPAs are strongly associated with early onset and 
rapid progression of bone lesions. As mentioned before, the 
pro-osteoclastogenic potency of IgG-ICs is greatly  deter-
mined by their sialylation levels, in that higher sialylation of 
the IgG-Fc glycon inhibits OC activation. ACPAs are found 
to be sialylated at a much lower level than random IgG, 
which is in accordance with the potency of ACPAs in bone 
damage. Artificially enhancing the sialylation levels of 
ACPA in vitro abolishes its activity in driving OC matura-
tion, which may act as a new strategy to treat human RA in 
the future. In fact, experiments in a CIA mouse model 
treated with ManNAc, a sialic acid precursor capable of 
increasing protein sialylation levels, has displayed promis-
ing efficacy (Harre et al., 2015). Activated B cells in RA not 
only produce antibodies (e.g., ACPAs) and secrete inflam-
matory cytokines but also express RANKL, all of which 
favor OC differentiation. Thus, the bone-protective efficacy 
of rituximab by depletion of B cells can be explained and 
expected (Dohn et al., 2009). 
The concept of osteoimmunology strengthens our under-
standing of the biologic agents that have now been widely 
used in RA therapy and provides potential targets for new 
strategies. Except for B cell depletion, cytokine inhibition, 
including via TNF inhibitors (etanercept, infliximab, ada-
limumab and golimumab) and IL-6 receptor blockade (to-
cilizumab), has been confirmed to be clinically effective in 
retarding the progression of the bone erosion process. 
CTLA4 switches off the costimulatory CD28:CD80/86 in-
teraction and provides a negative regulatory signal for OC 
differentiation (Axmann et al., 2008). CTLA4-Ig 
(abatacept) introduction into the therapy for active RA has 
also been proven to be effective (Schiff, 2011), and the 
mechanism is multifaceted, beyond T cell costimulation and 
activation (Cutolo et al., 2016) (Figure 2). 
OP (osteoporosis) 
Postmenopausal OP and glucocorticoid (GC)-induced OP 
(GIOP) are the main types of OP that rheumatologists usu-
ally encounter in routine practice. Decreased estrogen in the 
circulation after menopause will lead to OP, with bone re-
sorption outpacing bone formation. GCs are the indispensa-
ble cornerstone of the management of autoimmune disease,  
 
 
Figure 2  Components of osteoimmunology contribute to bone absorption in RA and target therapy. Immune cells interact with bone cells via cytokines and 
surface molecules to mediate bone erosion and inflammation-associated bone loss in RA. TNF-, IL-6 and IL-1 are the most important pro-inflammatory 
cytokines in this context, and RANKL is the primary signal in OC differentiation. These recommended therapeutic targets have been confirmed in clinical 
practice or are waiting for validation in clinical trials.   
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with potent suppressive effects on inflammation, but GC 
exposure is widely known for its adverse effects on bone 
remodeling, leading to a high risk of vertebral fracture and 
femur head necrosis. In particular, GCs inhibit bone for-
mation and promote bone resorption to accelerate bone loss, 
probably by prolonging the survival of OCs and inducing 
apoptosis of OBs and osteocytes (Mitra, 2011). Further re-
search indicates that GCs can inhibit the Wnt pathway, 
which is pivotal in OB differentiation, survival and func-
tion.  
New strategies to improve bone turnover and strengthen 
bone protection have been employed in OP. Denosumab, 
which is an antibody against RANKL, is effective in in-
creasing bone mineral density and reducing the bone frac-
ture risk in patients with OP and has been approved for 
postmenopausal OP treatment. Estrogen and estrogen re-
ceptor modulators are also effective in preventing bone loss 
in postmenopausal women, but adverse effects should be 
evaluated and monitored. Odanacatib, an inhibitor of ca-
thepsin K, exhibits similar bone protection effects, and ap-
proval can be expected soon. Other agents, such as a 
PTH-related peptide (PTHrp) analog and a Src tyrosine ki-
nase inhibitor, are at the stage of clinical or preclinical 
evaluations (Makras et al., 2015; Suresh and Abrahamsen, 
2015). 
SPA (spondyloarthropathy) 
Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) 
are representative SPA disorders with distinctive osteoclas-
togenic features. Syndesmophytes and enthesophytes, ver-
tebral bone loss and sacroiliac joint erosion with or without 
peripheral joint destruction coexist in SPA, indicating dis-
turbed bone remodeling. Enhanced Th17 cell numbers and 
IL-17 serum levels have also been observed and are be-
lieved to be involved in the pathogenesis (Mei et al., 2011; 
Raychaudhuri et al., 2015; Shen et al., 2009). IL-22 pro-
duced by Th17 cells exerts anabolic effects on bone remod-
eling by stimulating Wnt and BMP signaling and enhancing 
bone formation (Goldring, 2013). Dickkopf-1 (DKK-1) is a 
natural inhibitor of Wnt signaling that can induce OPG 
production and that is devoted to osteoblastogenesis. In 
contrast to increased DKK-1 in RA, serum DKK-1 in AS 
has been reported to be decreased and to be inversely corre-
lated with AS disease severity (Yucong et al., 2014). 
Blockade of DKK-1 in mice induces ankylosis of sacroiliac 
joints (Uderhardt et al., 2010), indicating that manipulating 
Wnt signaling may be a promising therapeutic strategy to 
prevent osteophyte formation at the inflammation site 
(Schett et al., 2008). 
PD (periodontal disease) 
PD is a chronic disease associated with alveolar bone loss 
and gingival tissue inflammation. Its etiology is an immune 
reaction to oral bacteria, and especially Porphyromonas 
gingivalis (P. gingivalis). The compromised periodontium 
will lose its supportive function, and the affected teeth will 
ultimately fall out. PD and RA are closely correlated with a 
high comorbidity and parallel severity (de Pablo et al., 
2008; Mercado et al., 2003). Both diseases have common 
risk factors, such as shared HLA-DRB1 epitope alleles and 
smoking. P. gingivalis is thought to be the major, although 
not exclusive, cause of PD. The pathogen specifically con-
tributes to protein citrullination, which subsequently stimu-
lates the host immune response and induces autoantigen 
production, acting as a trigger in the pathological reaction of 
RA (Lundberg et al., 2010). It has been reported that anti-
bodies to P. gingivalis are more commonly observed in RA 
patients and are significantly correlated with anti-cyclic 
citrullinated peptide (CCP) titers in RA patients, revealing 
the inherent connections between the two diseases (Mikuls 
et al., 2009). What’s more, a considerable proportion of 
Treg-derived IL-17 producing cells (IL-17+Foxp3+ T cells) 
have been found in PD lesions indicating the conversion 
from Treg to Th17 may play a role in the pathogenesis of 
PD (Okui et al., 2012). 
Periodontal bone loss is associated with increased infil-
tration of B cells and T cells with enhanced RANKL ex-
pression and is capable of inducing OC maturation in a 
RANKL-dependent manner (Kawai et al., 2006). Recently, 
Li et al. have found that silencing the Atp6v1c1 gene locally 
can reduce OC numbers and reverse bone destruction in PD 
as well as inhibiting DC and macrophage infiltration and 
down-regulating pro-inflammatory cytokine production (Li 
et al., 2015). Atp6v1c1 is expressed by OCs and localized 
on the ruffled border, and it is responsible for encoding a 
proton pump subunit that is required for OC-mediated ex-
tracellular acidification. The acidic milieu is required for 
solubilization of calcium from bone (Li et al., 1999).  
FUTURE PERSPECTIVES 
Advances in osteoimmunology expand and deepen our un-
derstanding of the underlying pathophysiological mecha-
nisms in certain osteoarticular disorders and systemic in-
flammatory diseases. Although the precise mechanisms 
underlying the intimate communication and regulation in-
volved remain to be elucidated, promising strategies have 
been developed based on current and growing knowledge in 
this field. Thinking of the skeletal system and immune sys-
tem as an integrated unit is paving the way to preventing 
bone loss and bone destruction, which affect enormous 
populations. As an osteoclastogenesis inducer, RANKL is 
theoretically a promising target in osteopenic disease. 
Denosumab, a human IgG2 monoclonal antibody against 
RANKL, has been approved to treat postmenopausal OP 
and bone metastases. A preliminary clinical trial has shown 
that Denosumab has certain effects in reducing the progres-
sion of RA (Cohen et al., 2008). Along with growing under-
standing of the pathological mechanisms of RA and the 
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wide use of TNF-blocking biologics with inspiring effects, 
knowledge of osteoimmunology is rapidly growing and 
expanding, and new strategies are emerging.  
CONCLUSIONS  
The skeletal system and immune system are closely corre-
lated, and growing knowledge of their interaction and in-
terdependence has given birth to the new interdisciplinary 
field of osteoimmunology. The RANK/RANKL/OPG triad 
acts as the central regulator of the crosstalk between the two 
systems. This triad is not only the pivotal mediator of oste-
oclastogenesis, leading to bone loss, but also an indispensa-
ble factor for LN organogenesis and B cell maturation, in 
addition to providing potent survival signals for DCs to ini-
tiate immune responses. Design of therapeutic approaches 
should consider these bidirectional effects. Manipulation of 
the OPG signal or intervention in RANKL expression and 
the expression of other signaling molecules involved may 
be promising to ameliorate osteopenic problems in multiple 
clinical disorders, regardless of their origin.  
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